<DOC>
	<DOCNO>NCT02743364</DOCNO>
	<brief_summary>This randomized phase II trial study well simvastatin work reduce pancreatitis ( inflammation pancreas ) patient pancreatitis occurs ( recurrent ) , worsen quickly ( acute ) , persist progressed long period time ( chronic ) . Simvastatin may decrease inflammation pancreas modulate immune response responsible inflammation . It yet know simvastatin may effective treatment pancreatitis .</brief_summary>
	<brief_title>Simvastatin Reducing Pancreatitis Patients With Recurrent , Acute Chronic Pancreatitis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate effect simvastatin intervention versus placebo change secretin-stimulated peak bicarbonate concentration pancreatic fluid 6 month post-treatment patient hospitalize acute chronic pancreatitis , prior history one episodes acute pancreatitis . SECONDARY OBJECTIVES : I . Change endoscopic ultrasound score ( EUS ) . II . Change fecal elastase . III . Change serum pancreatic fluid level C-reactive protein ( CRP ) , interleukin ( IL ) -6 , IL-10 , transform growth factor beta 1 ( TGFB1 ) , matrix metalloproteinase-9 ( MMP-9 ) , tumor necrosis factor alpha ( TNF-a ) , soluble ( ) -fractalkine . IV . Change pancreatic fluid level epithelial-mesenchymal transition ( EMT ) marker , e-cadherin vimentin . V. Change pancreatitis-related readmission . VI . Change Kirsten rat sarcoma viral oncogene homolog ( KRAS ) gene mutation pancreatic fluid . VII . Change quality life score measure quality life questionnaire core 30 ( QLQ-C30 ) quality life questionnaire pancreatic modification ( QLQ-PAN28 ) chronic pancreatitis ( CP ) . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients receive simvastatin orally ( PO ) daily ( QD ) 6 month . ARM II : Patients receive placebo PO QD 6 month . After completion study treatment , patient follow 30 , 60 , 90 day .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Recurrent pancreatitis ( least two episode acute pancreatitis past 12 month ) confirm 2 following : ( 1 ) typical upper abdominal pain ; ( 2 ) elevation serum amylase lipase &gt; = 3 time upper limit normal ; ( 3 ) feature acute pancreatitis crosssectional imaging Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Leukocytes &gt; = 2,500/microliter Absolute neutrophil count &gt; = 1,500/microliter Platelets &gt; = 100,000/microliter Hemoglobin within normal institutional limit Total bilirubin = &lt; 1.5 × institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 1.5 × institutional ULN ; patient whose AST/ALT level normalize screen 2 abnormal test include trial Creatinine within normal institutional limit Women childbearing potential must confirm negative pregnancy test result prior enrollment Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform study physician immediately ; woman receive treatment simvastatin breastfeed infant Ability understand willingness sign write informed consent document medical release Willing able comply trial protocol followup Prior current use statin medication , current use gemfibrozil , cyclosporine , danazol , lomitapide , verapamil , diltiazem , dronedarone , amiodarone , amlodipine , ranolazine , strong cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor ( e.g. , itraconazole , ketoconazole , posaconazole , voriconazole , human immunodeficiency virus [ HIV ] protease inhibitor , boceprevir , telaprevir , erythromycin , clarithromycin , telithromycin , nefazodone , cobicistatcontaining product ) History chronic myopathy Current use investigational agent History adverse effect , intolerance , allergic reaction attribute compound similar chemical biologic composition simvastatin ( i.e. , statin medication ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Women pregnant breastfeed Presence gallstone hypertriglyceridemia ( level great 800 mg/dl ) require medical surgical intervention ; note : include patient independent episode pancreatitis cholecystectomy , exclude patient candidate cholecystectomy History active malignancy ( exclude basal/squamous cell skin cancer ) Known active infection HIV Concurrent illness , know psychiatric disorder substance abuse ( i.e. , average alcohol consumption 3 drink per day ) , opinion investigator would compromise either patient integrity data Abnormal liver function test screen 2 ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 1.5 institutional upper limit normal [ ULN ] ) Recurrent pancreatitis episode iatrogenic ( endoscopic retrograde cholangiopancreatography [ ERCP ] induce )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>